MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development

Blood

Volumn 125, Issue 12, 2015, Pages 1910-1921

  Sheikh, Bilal N ^a,b   Lee, Stanley C W ^a,b   El Saafin, Farrah ^a,b   Vanyai, Hannah K ^a,b   Hu, Yifang ^a   Pang, Swee Heng Milon ^a,b   Grabow, Stephanie ^a,b   Strasser, Andreas ^a,b   Nutt, Stephen L ^a,b   Alexander, Warren S ^a,b   Smyth, Gordon K ^a,c   Voss, Anne K ^a,b   Thomas, Tim ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE MOZ; HOMEODOMAIN PROTEIN; MONOCYTIC LEUKEMIA ZINC FINGER PROTEIN; RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; MOZ PROTEIN, MOUSE; MYC PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKITT LYMPHOMA; CELL AGING; CHROMOSOME TRANSLOCATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HAPLOINSUFFICIENCY; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HOMEOBOX; LEUKEMOGENESIS; LYMPHOMA; LYMPHOMA CELL; MONOCYTIC LEUKEMIA; MOUSE; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; ALLELE; ANIMAL; B LYMPHOCYTE; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; FEMALE; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; SEQUENCE ANALYSIS; STEM CELL;

ALLELES; ANIMALS; B-LYMPHOCYTES; CELL AGING; CELL DIFFERENTIATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOINSUFFICIENCY; HISTONE ACETYLTRANSFERASES; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-MYC; SEQUENCE ANALYSIS, RNA; STEM CELLS; TRANSCRIPTION, GENETIC;

EID: 84925379433     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-594655     Document Type: Article

References (59)

1. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447(7143):407-412.
2. Cui K, Zang C, Roh TY, et al. Chromatin signatures in multipotent human hematopoietic stem cells indicate the fate of bivalent genes during differentiation. Cell Stem Cell. 2009;4(1):80-93.
3. Butler JS, Dent SY. The role of chromatin modifiers in normal and malignant hematopoiesis. Blood. 2013;121(16):3076-3084.
4. Rice KL, Hormaeche I, Licht JD. Epigenetic regulation of normal and malignant hematopoiesis. Oncogene. 2007;26(47):6697-6714.
5. Doyon Y, Cayrou C, Ullah M, et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell. 2006;21(1):51-64.
6. Borrow J, Stanton VP Jr, Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996;14(1):33-41.
7. Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pébusque MJ. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer. 2000; 28(2):138-144.
8. Carapeti M, Aguiar RC, Goldman JM, Cross NC. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood. 1998;91(9):3127-3133.
9. Esteyries S, Perot C, Adelaide J, et al. NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia. 2008;22(3): 663-665.
10. Deguchi K, Ayton PM, Carapeti M, et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell. 2003;3(3):259-271.
11. Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6(6):587-596.
12. Sun T, Wu E. Acute monoblastic leukemia with t(8;16): a distinct clinicopathologic entity; report of a case and review of the literature. Am J Hematol. 2001;66(3):207-212.
13. Stark B, Resnitzky P, Jeison M, et al. A distinct subtype of M4/M5 acute myeloblastic leukemia (AML) associated with t(8:16)(p11:p13), in a patient with the variant t(8:19)(p11:q13) - case report and review of the literature. Leuk Res. 1995;19(6):367-379.
14. Gervais C, Murati A, Helias C, et al Groupe Francophone de Cytogénétique Hématologique. Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique. Leukemia. 2008;22(8):1567-1575.
15. Thomas T, Corcoran LM, Gugasyan R, et al. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev. 2006;20(9):1175-1186.
16. Perez-Campo FM, Borrow J, Kouskoff V, Lacaud G. The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. Blood. 2009;113(20):4866-4874.
17. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318(6046):533-538.
18. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669.
19. Strasser A, Harris AW, Bath ML, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 1990;348(6299):331-333.
20. Voss AK, Collin C, Dixon MP, Thomas T. Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. Dev Cell. 2009;17(5):674-686.
21. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 1996; 85(1):27-37.
22. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4(1):1-7.
23. Lee SC, Phipson B, Hyland CD, et al. Polycomb repressive complex 2 (PRC2) suppresses Em-myc lymphoma. Blood. 2013;122(15):2654-2663.
24. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41(10):e108.
25. Law CW, Chen Y, Shi W, Smyth GK. Voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.
26. Wu D, Lim E, Vaillant F, Asselin-Labat ML, Visvader JE, Smyth GK. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics. 2010;26(17):2176-2182.
27. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353-371.
28. Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ. 2009;16(5):684-696.
29. Strasser A, Elefanty AG, Harris AW, Cory S. Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 1996;15(15):3823-3834.
30. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol. 2001;2(10): 731-737.
31. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13(20):2670-2677.
32. Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56-67.
33. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151(1):68-79.
34. Lawrence HJ, Christensen J, Fong S, et al. Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood. 2005;106(12): 3988-3994.
35. Paggetti J, Largeot A, Aucagne R, et al. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells. Oncogene. 2010;29(36):5019-5031.
36. Yu BD, Hess JL, Horning SE, Brown GA, Korsmeyer SJ. Altered Hox expression and segmental identity in Mll-mutant mice. Nature. 1995;378(6556):505-508.
37. Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell. 2007;1(3):324-337.
38. Li BE, Gan T, Meyerson M, Rabbitts TH, Ernst P. Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood. 2013;122(12):2039-2046.
39. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002;30(1):41-47.
40. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1(2):133-143.
41. Camós M, Esteve J, Jares P, et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 2006;66(14):6947-6954.
42. Haferlach T, Kohlmann A, Klein HU, et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23(5):934-943.
43. Penkov D, Mateos San Martín D, Fernandez-Díaz LC, et al. Analysis of the DNA-binding profile and function of TALE homeoproteins reveals their specialization and specific interactions with Hox genes/proteins. Cell Reports. 2013;3(4): 1321-1333.
44. Calvo KR, Knoepfler PS, Sykes DB, Pasillas MP, Kamps MP. Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proc Natl Acad Sci USA. 2001;98(23):13120-13125.
45. Calvo KR, Sykes DB, Pasillas M, Kamps MP. Hoxa9 immortalizes a granulocyte-macrophage colony-stimulating factor-dependent promyelocyte capable of biphenotypic differentiation to neutrophils or macrophages, independent of enforced meis expression. Mol Cell Biol. 2000;20(9):3274-3285.
46. Hoffmann R, Seidl T, Neeb M, Rolink A, Melchers F. Changes in gene expression profiles in developing B cells of murine bone marrow. Genome Res. 2002;12(1):98-111.
47. Mao Z, Ke Z, Gorbunova V, Seluanov A. Replicatively senescent cells are arrested in G1 and G2 phases. Aging (Albany NY). 2012;4(6):431-435.
48. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69(1):119-128.
49. Perez-Campo FM, Costa G, Lie ALM, Stifani S, Kouskoff V, Lacaud G. MOZ-mediated repression of p16(INK) (4) (a) is critical for the self-renewal of neural and hematopoietic stem cells. Stem Cells. 2014;32(6):1591-1601.
50. Voss AK, Vanyai HK, Collin C, et al. MOZ regulates the Tbx1 locus, and Moz mutation partially phenocopies DiGeorge syndrome. Dev Cell. 2012;23(3):652-663.
51. Sanyal M, Tung JW, Karsunky H, et al. B-cell development fails in the absence of the Pbx1 proto-oncogene. Blood. 2007;109(10):4191-4199.
52. Shen WF, Montgomery JC, Rozenfeld S, et al. AbdB-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins. Mol Cell Biol. 1997;17(11):6448-6458.
53. Ariki R, Morikawa S, Mabuchi Y, et al. Homeodomain transcription factor Meis1 is a critical regulator of adult bone marrow hematopoiesis. PLoS ONE. 2014;9(2):e87646.
54. Sheikh BN, Downer NL, Kueh AJ, Thomas T, Voss AK. Excessive versus physiologically relevant levels of retinoic acid in embryonic stem cell differentiation. Stem Cells. 2014;32(6):1451-1458.
55. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535-1548.
56. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet. 2007;370(9583):240-250.
57. Hilden JM, Dinndorf PA, Meerbaum SO, et al Children's Oncology Group. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108(2):441-451.
58. Moorman AV, Harrison CJ, Buck GA, et al Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8): 3189-3197.
59. Falk H, Connor T, Yang H, et al. An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets. J Biomol Screen. 2011;16(10):1196-1205.